

Ref No.: QHTL/Sec/SE/2018-19/58

13th February, 2019

The Manager,
Corporate Services,
BSE Limited,
14th floor, P J Towers, Dalal Street,
Mumbai – 400 001
Ref: Security ID : QUICKHEAL
Security Code: 539678

The Manager,
Corporate Services,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Symbol: QUICKHEAL
Series : EQ

Subject: Outcome of Board Meeting 13th February, 2019

Dear Sir / Madam,

We wish to inform you that the Board of Directors at its meeting held on 13th February, 2019 which commenced at 03:30 PM and concluded at 6:45 PM, has approved following:

1. Unaudited Standalone Financial Results of the Company for the quarter and nine months ended 31st December, 2018.
2. Pursuant to Regulation 33 of SEBI Regulations, we have enclosed herewith Limited Review Report for the Unaudited Standalone Financial Results of the Company for the quarter and nine months ended 31st December, 2018, from our Statutory Auditors, M/s S R B C & CO LLP, Chartered Accountants.
3. A copy of the Press Release being issued in respect of aforesaid financial results.
4. Result Presentation in respect of aforesaid financial results.

This is for your information and records.

For Quick Heal Technologies Limited

Vinav Agarwal
Associate Company Secretary

Encl: As Above



QUICK HEAL TECHNOLOGIES LIMITED


Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014

CIN: L72200MH1995PLC091408

STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2018

(INR in million)

Sr. No.	Particulars	Standalone					
		Quarter ended			Nine month ended		Year ended
		December 31, 2018 (Unaudited)	September 30, 2018 (Unaudited)	December 31, 2017 (Unaudited)	December 31, 2018 (Unaudited)	December 31, 2017 (Unaudited)	March 31, 2018 (Audited)
1	Income						
	Revenue from operations	659.05	1,088.56	635.88	2,275.49	1,978.42	3,162.22
	Other income	90.10	86.35	51.70	240.20	163.27	298.75
	Total income	749.15	1,174.91	687.58	2,515.69	2,141.69	3,460.97
2	Expenses						
	Cost of raw materials consumed	8.62	10.31	(2.60)	20.73	1.39	10.55
	Purchase of security software products	22.28	41.42	17.44	82.92	42.19	93.96
	Increase / (decrease) in inventories of security software products	(2.28)	(5.36)	8.07	(10.58)	30.48	22.02
	Employee benefits expense	241.25	243.51	237.61	735.63	750.26	996.76
	Depreciation and amortisation expense	59.74	60.12	67.94	179.00	199.67	268.82
	Other expenses	179.73	195.90	244.18	541.83	577.90	801.62
	Total expenses	509.34	545.90	572.64	1,549.53	1,601.89	2,193.73
3	Profit / (loss) before exceptional items and tax (1-2)	239.81	629.01	114.94	966.16	539.80	1,267.24
4	Exceptional items (refer note 4)	-	50.00	3.28	50.00	3.28	75.09
5	Profit / (loss) before tax (3-4)	239.81	579.01	111.66	916.16	536.52	1,192.15
6	Tax expense						
	Current tax						
	Pertaining to profit for the current period	78.70	191.27	27.71	299.66	154.82	363.68
	Adjustments of tax relating to earlier periods (Net)	-	14.71	-	14.71	-	-
	Deferred tax	0.18	(4.01)	4.28	(0.59)	20.16	39.69
	Total tax expense	78.88	201.97	31.99	313.78	174.98	403.37
7	Profit / (loss) for the period (5-6)	160.93	377.04	79.67	602.38	361.54	788.78
8	Other comprehensive income, net of tax						
	Other comprehensive income not to be reclassified to profit or loss in subsequent periods:						
	Re-measurement of defined benefit plans	(0.32)	1.36	3.49	(3.65)	3.62	7.35
	Net (loss) or gain on FVTOCI assets (refer note 4)	-	(29.52)	-	(29.52)	-	(37.13)
	Other comprehensive income to be reclassified to profit or loss in subsequent periods:						
	Exchange differences on translation of foreign operations	-	-	-	-	-	-
	Total other comprehensive income	(0.32)	(28.16)	3.49	(33.17)	3.62	(29.78)
9	Total comprehensive income (after tax) (7+8)	160.61	348.88	83.16	569.21	365.16	759.00
10	Paid-up equity share capital (face value of INR 10 each)	705.53	704.89	703.20	705.53	703.20	703.88
11	Other equity (as per balance sheet of previous accounting year)						6,667.44
12	Earnings per share of INR 10 each: (not annualised except for the year ended March)						
	a) Basic	2.28	5.35	1.13	8.54	5.15	11.23
	b) Diluted	2.28	5.34	1.13	8.53	5.14	11.20



Handwritten signature/initials

QUICK HEAL TECHNOLOGIES LIMITED
 Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014
 CIN: L72200MH1995PLC091408
STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2018

Notes to financial results

- 1 The above financials results for the quarter and nine month ended December 31, 2018 have been subjected to limited review by the statutory auditors of the Company and reviewed by the Audit Committee and approved by the Board of Directors of the Company at the meetings held on February 13, 2019.
- 2 During the earlier periods, the Company had received the statements of demand of Service Tax under the provision of Finance Act, 1994 for INR 1,223.07 million (excluding penalty of INR 626.97 million and pre-deposit if any) for the period March 01, 2011 to March 31, 2016 on supply of anti-virus software Compact Disk. The Company has filled the appeal with Customs, Excise and Service Tax Appellate Tribunal. In addition to this, the Company had received letters for submission of the sales information pertaining to period April 01, 2016 June 30, 2017. Accordingly, the Company had submitted the required information during the earlier periods.

Based on technical circular issued by the government authorities and an independent legal opinion, the Company is confident of getting this claim set aside and accordingly no provision has been considered necessary in this regard.
- 3 Effective April 1, 2018, the Company has adopted Ind AS 115 revenue from contracts with customers under the modified retrospective approach without adjustment of comparatives. The standard is applied to contracts that remains in force as at April 01, 2018. The application of the standards did not have any significant impact on the retained earnings as at April 01, 2018 and financial results for the current quarter and nine month ended December 31, 2018.
- 4 **Impairment of investments**
Included in exceptional items
(INR in million)


Particulars	Quarter ended			Nine month ended		Year ended
	December 31, 2018 (Unaudited)	September 30, 2018 (Unaudited)	December 31, 2017 (Unaudited)	December 31, 2018 (Unaudited)	December 31, 2017 (Unaudited)	March 31, 2018 (Audited)
Impairment of investment in wholly owned subsidiaries	-	50.00	3.28	50.00	3.28	75.09

Further, the decline in fair value of investment of INR 29.52 million in Smartalyse Technologies Private Limited (March 31, 2018; INR 37.13 million) has been included in Other Comprehensive income.
- 5 The Company is engaged in providing security software solutions. The Chief Operating Decision Maker (CODM) reviews the information pertaining to revenue of each of the target customer group (segments) viz. retail, enterprise & government and mobile. However, based on similarity of activities/products, risk and reward structure, organisation structure and internal reporting systems, the Company has structured its operations into one operating segment viz. anti-virus and as such there is no separate reportable operating segment as defined by Ind AS 108 "Operating segments".
- 6 Post implementation of Goods and Services Tax (GST) w.e.f. July 1, 2017, "Revenue from operations" has been disclosed net of GST.

For and on behalf of the Board of Directors


Kailash Katkar
 Managing Director
 & Chief Executive Officer

Place: Pune
 Date: February 13, 2019



QUICK HEAL TECHNOLOGIES LIMITED
 Regd. Office : Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014
 CIN: L72200MH1995PLC091408

ABRIDGED STATEMENT OF FINANCIAL RESULTS

(INR in million)

Sr. No.	Particulars	Standalone					
		Quarter ended			Nine month ended		Year ended
		December 31, 2018 (Unaudited) (Refer note 2)	September 30, 2018 (Unaudited)	December 31, 2017 (Unaudited) (Refer note 2)	December 31, 2018 (Unaudited)	December 31, 2017 (Unaudited)	March 31, 2018 (Audited)
1	Total income from operations (net)	659.05	1,088.56	635.88	2,275.49	1,978.42	3,162.22
2	Net profit/(loss) for the period before tax (before exceptional items)	239.81	629.01	114.94	966.16	539.80	1,267.24
3	Net profit/(loss) for the period before tax (after exceptional items)	239.81	579.01	111.66	916.16	536.52	1,192.15
4	Net profit/(loss) for the period after tax (after exceptional items)	160.93	377.04	79.67	602.38	361.54	788.78
5	Total Comprehensive Income for the period [comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	160.61	348.88	83.16	569.21	365.16	759.00
6	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)	-	-	-	-	-	6,667.44
7	Equity share capital (Face value of ₹ 10 each)	705.53	704.89	703.20	705.53	703.20	703.88
8	Earnings per share (before and after extraordinary items) (of ₹10 each) - not annualised						
	Basic:	2.28	5.35	1.13	8.54	5.15	11.23
	Diluted:	2.28	5.34	1.13	8.53	5.14	11.20

Notes:

- The above is an extract of the detailed format of nine months and Quarter Financial Results filed with the Stock Exchange under Regulation 33 of the Securities and Exchange Board of India ('SEBI') (Listing obligations and Disclosure Requirements ('LODR') Regulations, 2015. The full format of the audited standalone financial results of the Company are available on the Stock Exchange's website (www.bseindia.com and www.nseindia.com) and also on the Company's website - www.quickheal.co.in.
- The above financials results for the quarter and nine month ended December 31, 2018 have been subjected to limited review by the statutory auditors of the Company and reviewed by the Audit Committee and approved by the Board of Directors of the Company at the meetings held on February 13, 2019.



For and on behalf of the Board of Directors
Sd/-

Kailash Katkar
Managing Director
& Chief Executive Officer

Place: Pune

Date: February 13, 2019



Limited Review Report - Ind AS Standalone Financial Results**Review Report to
The Board of Directors
Quick Heal Technologies Limited**

1. We have reviewed the accompanying statement of unaudited standalone Ind AS financial results of Quick Heal Technologies Limited (the 'Company') for the quarter ended December 31, 2018 and year to date from April 01, 2018 to December 31, 2018 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Regulation'), read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 ('the Circular').
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015, as amended, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.



S R B C & CO LLP

Chartered Accountants

5. We draw attention to note 2 of the Statement, wherein it is stated that the Company had received statements of demand of service tax under the provision of Finance Act, 1994 for INR 1,223.07 million (excluding penalty of INR 626.97 million) for the period from March 01, 2011 to March 31, 2016. Our conclusion is not qualified in respect of this matter.

For S R B C & CO LLP

Chartered Accountants

ICAI Firm registration number: 324982E/E300003



per Tridevlal Khandelwal

Partner

Membership No.: 501160

Place: Pune

Date: February 13, 2019



FOR IMMEDIATE RELEASE

Quick Heal Technologies Limited reports 15% revenue growth during 9M FY19

- Revenue grew YoY by 15% to Rs. 2,289 million
- EBITDA grew YoY by 63% to Rs. 893 million with a Margin of 39%
- PAT grew YoY by 89% to Rs. 641 million with an improvement in Margin to 28%

PUNE, February 13, 2019: Quick Heal Technologies Limited (“Quick Heal”), India’s leading provider of IT Security Software Products and Solutions to individuals, businesses and Government, reported its reviewed and un-audited results for the quarter and nine month ending 31st December 2018.

Consolidated Financial Highlights:

Particulars (Rs. million)	9M FY19	9M FY18	YoY Change
Revenue	2,289.25	1,996.23	14.68%
EBITDA	892.80	548.95	62.64%
EBITDA Margin	39.00%	27.50%	+1,150 bps
PAT	640.77	338.27	89.43%
PAT Margin	27.99%	16.95%	+1,104 bps

Segmental Performance for the nine month ended 31st December 2018

- Retail segment revenue up 15% to Rs. 1,924 million as compared to Rs. 1,680 million in the corresponding period of the previous year
 - ✓ Contributes 80% to Total Revenue
- Enterprise and Government segment revenue up 7% to Rs. 490 million as compared to Rs. 456 million in the corresponding period previous year
 - ✓ Contributes 20% to Total Revenue

Mr. Kailash Katkar, Managing Director & Chief Executive Officer, Quick Heal Technologies Limited, said; “There has been a sustained momentum in the business with an overall revenue growth of 15% in our YTD operating performance. During the year, we made conscious efforts to offer highly customised endpoint security, network security and data protection solutions to our enterprise customers and enhance engagement with the channel ecosystem. While retail segment grew by 15%, the growth of 7% in the Enterprise and Government segment has been lower than our expectations. However, we are confident

that our leadership position backed by world-class products & solutions and deep intelligence on the threat landscape will enable us to deliver steady performance in the coming future.”

Mr. Nitin Kulkarni, Chief Financial Officer, Quick Heal Technologies Limited, added “*Our unrelenting efforts to grow the business have started yielding results. For 9MFY19, we have witnessed a 15% growth in revenue which has been complemented by increase in EBITDA and PAT margins by 1,150 bps and 1,104 bps respectively. As of December 2018, overall working capital days stood at 77 days as compared to 83 days in March 2018.*”

Mr. Vijay Mhaskar, Chief Operating Officer, Quick Heal Technologies Limited, commented “*Our customers recognise and appreciate the superior protection, timely updates and cross-product integration delivered by our solutions. Our thrust on new innovations using artificial intelligence and machine learning will help us further strengthen our portfolio and keep us ahead of the curve in providing solutions to tackle the evolving cyber threat landscape. We continue to remain optimistic on the growth prospects in retail as well as enterprise & government segment in the coming future.*”

Award and Accreditation:-

- Seqrite received best cybersecurity brand award at the ‘National Summit for Digital Innovation & Cybersecurity’

About Quick Heal Technologies Limited

Quick Heal Technologies Limited is one of the leading providers of IT security software products and solutions to individuals, businesses and Government. Incorporated in 1995 with a registered office in Pune, Quick Heal has a network of over 25,000 channel partners as on 31st December 2018. It conducts sales and marketing activities across India.

Quick Heal’s portfolio includes solutions under the widely recognized brand names ‘Quick Heal’ and ‘Seqrite’ across various operating systems and devices.

For more information about the Company, please visit our website www.quickheal.co.in

Safe Harbor Statement

This document may contain forward-looking statements about Quick Heal Technologies Limited, which are based on the beliefs, opinions, and expectations of the company’s management as the date of this press release and the companies do not assume any obligation to update their forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. These statements are not the

guarantees of future performance and involve risks and uncertainties that are difficult to predict. Consequently, readers should not place any undue reliance on such forward-looking statements.

For further details please contact

Company	Investor Relations Advisors
Quick Heal Technologies Limited CIN No: L72200MH1995PLC091408 Mr. Akash Gosavi Email Id: akash.gosavi@quickheal.co.in Tel. No.: +91 020 6681 3287	Strategic Growth Advisors Pvt. Ltd. CIN No: U74140MH2010PTC204285 Mr. Jigar Kavaia / Mr. Rahul Agarwal Email Id: jigar.kavaia@sgapl.net rahul.agarwal@sgapl.net Tel No: +91 77383 59389 / +91 79770 90416



Quick Heal

Investor Presentation

February 2019

This presentation and the accompanying slides (the “Presentation”), which have been prepared by Quick Heal Technologies Ltd. (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward looking statements concerning the Company’s future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.

Value Proposition



20+ Years of Quick Heal Technologies...

Our Brands



Business Segments



Home and SOHO



SME



Government and Enterprise

Platforms



Desktop



Laptop



Mobile



Notepad



Server

34%

Market Share in
Retail Segment in
India

9 Million

Number of Active
Licenses globally

32,500+

Enterprise Customers

4

No. of Patents in US

25,000+

No. of Partners in India

40 Countries

Global Presence

* Market Share Source : Zinnov Research



Vision

To be the trusted Global Leader in securing the Digital World



Mission

- Secure our Customers by providing Innovative, most preferred and valued Security Solutions, Services and Knowledge.
- Protect information and interactions on all types of networks, devices & things globally.
- Build a healthy business and organization.

...of offering Complete Security Solutions

Quick Heal

Security Simplified

SEQRITE

Retail

- Quick Heal Total Security
- Quick Heal Internet Security
- Quick Heal AntiVirus Pro
- Quick Heal Total Security For Mac
- Quick Heal AntiVirus for Server
- Quick Heal PCTuner 3.0
- Quick Heal Total Security Multi Device

Mobile

- Quick Heal Total Security for Android
- Quick Heal Antivirus for Mobile
- Quick Heal Mobile Security for Android
- Quick Heal Tablet Security for Android
- Fonetastic Pro
- Quick Heal Optimizer for iOS
- Quick Boost for iOS

SME / Enterprise

- Seqrite Endpoint Security
- Seqrite Endpoint Security Cloud
- Seqrite UTM
- Seqrite mSuite
- Seqrite Encryption
- Seqrite Secure Web Gateway
- Data Loss Prevention (DLP) Windows & MAC
- Seqrite Services

Enhance and Innovate Computer and Network Security Solutions through Strong Customer-focused Approach

...supported by Skilled Professionals



Sales and Marketing Team

Working closely with our customers and Channel Partners to identify new sales prospects, sell solutions and provide after-sales support.



Research & Development Team

Working on identifying new threats and devising innovative solutions and features across retail, enterprise and mobile segments with more than 2 decades of experience



Technical Support Team

Provide efficient multilingual and instant technical support, after sales service and effective guidance to domestic and overseas customers



...with strong Research & Development leading to Innovations



Product Management Team
Ensures that we build the Right Products for the Right Markets at the Right Time



Internet of Things (IoT) Security Team
Creating solutions to ensure all your connected devices are secure



Product Development Team
Designing & building cutting edge products & solutions



Incidence Response Team
Ensures customers are unaffected by critical attacks/outages by responding promptly




Quality Assurance Team
Relentlessly maintaining and creating industry benchmarks for quality




Security Labs
Detect and analyze threat vectors across the globe and provide advanced protection to customers

R&D Team Members



R&D Spend as % of Sales



...striving for excellence in customer service



Multi-lingual end user support in English, Hindi and several other major regional Indian languages



Availability of data sheets, product videos and manuals on website for providing information on technical specifications, installation guide, upgrade mechanisms



Release of various articles, technical papers, quarterly threat reports and conducting webinars in the area of security software

...Sales & Distribution to increase Market Share



 Sales & Support offices across India

Established a robust & diversified network and a dynamic ecosystem of Channel Partners in cities & towns across India to reach our end-customers

Strong **Internal Sales & Marketing Team** work closely with Customers and Channel Partners to identify new sales prospects, sell solutions and provide after-sales support

24,573
Total Retail Partners

363
Enterprise Partners

86
Government Partners

...guided by Experienced Board of Directors



Dr. KAILASH KATKAR
MD & CEO

Drives the strategic direction for the company while nurturing a strong leadership team to drive its execution



Mr. SANJAY KATKAR
Joint MD & CTO

Spearheads the creation and subsequent development of the core product technology



Mr. PRADEEP BHIDE
Independent director

Ex-IAS officer and served in senior positions at the State Government and Central Government



Mr. MANU PARIPIA
Independent Director

Founded Geometric Limited and has 35+ years of experience in the PLM and Engineering arena



Ms. PRITI RAO
Independent Director

Has 24 years of diverse experience in building and delivering a range of IT services for customers located across five continents



Mr. SHAILESH LAKHANI
Non Executive Director

Serves as the MD at Sequoia Capital India. Previously, he worked at Redknee's India subsidiary as the Managing Director



Mr. MEHUL SAVLA
Independent Director

Serves as Director for RippleWave Equity Advisors LLP. Previously worked at JP Morgan, ICICI Securities and SEBI



Dr. APURVA JOSHI
Independent director

Certified bank forensic accounting professional and anti – money laundering expert

... and Strong Leadership Team



Dr. Kailash Katkar | Managing Director & CEO

- Has been the driving force in growing Quick Heal Technologies since it's inception
- A proven leader with a profound proficiency in developing strong client relationships, passion for building outstanding teams and a disciplined focus on operations & execution of strategy



Mr. Nagesh Ayyagari | Vice President – Engineering, R&D

- Seasoned technology professional with a reputation for building and inspiring high-performance teams that delivered inline with company
- 20+ years of experience in leadership positions at Mphasis Software, McAfee, and Oracle
- Has management degrees from IIM, Bangalore and ESADE Business School & has done project management from UCB



Mr. Sanjay Katkar | Joint Managing Director & CTO

- Co-founder of the company
- Leads the global technology strategy & is responsible for the core research & development of the products
- Has served as the Director of Association of Anti-Virus Researchers, Asia and is a distinguished speaker at various industry forums
- Holds Master's degree in Computer Science from University of Pune



Mr. Deepak Mishra | Head, Retail Sales

- Responsible for enhancing market share and driving channel strategy for the retail brand
- 19+ years of experience in FMCG, Beverages, Telecom and IT Industries
- Has extensive exposure in Sales and Distribution, channel management, and building a robust distribution to drive productivity and profitability



Mr. Vijay Mhaskar | COO

- Responsible for formulating & driving the overall business strategy and operations across all business verticals
- 20+ years of experience in accelerating engineering processes & leading several successful products at Avaya, Symantec, Saba Inc., Clarice Technologies
- A Gold Medalist in Electrical Engineering & holds a Masters degree in Technology from IIT, Mumbai



Mr. Jyotish Werulkar | Head, Enterprise Sales

- Responsible for leading and driving the enterprise channel strategy & for building and managing the entire enterprise sales vertical in India
- 14+ years of experience in sales and business development at IBM, Acer India, AMD India
- Holds an MBA from University of Pune




Mr. Nitin Kulkarni | CFO

- 25+ years of experience in managing different aspects of finance function in IT and Manufacturing Industry
- Previously held leadership positions at Tech Mahindra, KPIT, Atlas Copco India and Persistent Systems
- A member of the Institute of Chartered Accountants of India



Mr. Gurudutt Jakhmola | Head, Government Sales

- A veteran Business Development professional with 16+ years of work experience in Government, Enterprise & SMB segment
- His core competencies include OEM Strategic Alliances, national/regional distribution and local Re-seller Network
- 18+ years of experience at firms such as Hutch, HP, and Reliance Broadcast Network Ltd



Quick Heal Global Offices

- 01

INDIA (HO)
Quick Heal Technologies Ltd.
- 02

USA
Quick Heal Technologies America Inc
- 03

KENYA
Quick Heal Technologies Africa Ltd.
- 04

UAE
Quick Heal Technologies (DMCC) FZE
- 05

JAPAN
Quick Heal Japan KK.

International Partner Locations

Benin	Bangladesh	Austria
Ghana	Japan	France
Gambia	Cambodia	Italy
Kenya	Korea	Netherlands
Malawi	Sri Lanka	Poland
Togo	Myanmar	Australia
Uganda	Malaysia	United Arab Emirates
South Africa	Nepal	Iran
Zambia	Philippines	United States
Zimbabwe	Vietnam	Venezuela

...certified by Global Agencies



International
Certifications
&
ISO Certifications



...trusted by our Customers

Our products help secure the networks used by millions of customers.
Some of the industries we cater to:

Gems &
Hospitality Jewellery Education
Automotive Manufacturing
IT & ITES
BFSI Pharma & Healthcare

...creating Specialized workforce at Quick Heal Academy



Popular Courses:

- ✓ Cyber Security and Forensics
- ✓ Cyber Threat Intelligence
- ✓ Malware Analysis & Reverse Engineering
- ✓ Cyber Law
- ✓ Electronic Crime Scene Investigation

Offerings:



Recent Developments

- Approval to conduct 6 Months Certification course at Deen Dayal Upadhyaya College, a constituent college of the University of Delhi
- Conducting training for Faculty Members and School Students of Maharashtra Cosmopolitan Education Society

Academy Partners:



Savitribai Phule Pune University

- Designed an 'M-Tech in Information Technology Program' for Savitribai Phule Pune University



Maharashtra Cosmopolitan Education Society

- The society runs 30 institutes from its ultra modern campuses located in Maharashtra



Quantum Global Campus

- MoU with Quantum Global Campus for a joint B. Tech programme



Chitkara University

- MoU with Chitkara University
- Introduced an additional stream in Cyber Security for the 4-year Undergraduate program



Gujarat Forensic Sciences University

- MoU with Gujarat Forensic Sciences University during Vibrant Gujarat 2017

...Awards & Accreditations as testimony to Delivery



- Best Make in India Brand, 14th VARINDIA IT Forum
- 12th Annual Info Security PG's 2016 Global Excellence Awards, USA
- Best Antivirus, 9th NCN Most Innovative Product of the Year Award
- Top Trademark Driven Industry (Small & Medium Enterprise) by CII Industrial Intellectual Property Awards



- Quick Heal Total Security receives BEST+++ certification from AVLab
- Seqrite Endpoint Security: Best Overall Speed 2017: Silver Award for the Performance Test
- Seqrite Endpoint Security is Approved Corporate Endpoint Protection for Windows by AV-Test
- Approved Windows Security Product for year 2017 by AV-Comparatives
- Seqrite Endpoint Security is ICSALabs certified product for year 2017




- Seqrite received Best Enterprise IT Security Brand award at 11th NCN innovative product award 2018
- Quick Heal Total Security (Windows) achieved one of the best protection rate in AV-Comparatives test
- Seqrite Endpoint Security certified as 'Approved Corporate Endpoint Protection' for Windows by 'AV-Test'
- Seqrite received best cybersecurity brand award at National Summit on Digital Innovation & Cybersecurity Summit


Product Offerings



Product Portfolio across Business Segments



Revenue Break-up – 9M FY19



Retail / SMB – Drives Scalability



- Core Protection
- Privacy Protection
- Safe Banking Features
- Web Security
- Parental Controls
- Stealth Mode
- Email Security
- Anti- Key Logger
- Track My Laptop
- Data Theft Protection
- PCTuner
- Improved Scan Engine
- Virtual Keyboard
- PC2 Mobile Scan
- QH Remote Device Management



Mobile Security – Huge Future Opportunity

► Growth Opportunities

- Customers understanding the need for Mobile Security
- Vast Untapped Market Potential




- 🔒 Background Scan
- 🔒 Security & Privacy Advisor
- 🔒 SafePe
- 🔒 Cloud Backup
- 🔒 Call & Message Filter
- 🔒 Register with TRAI
- 🔒 Anti-Theft Technology
- 🔒 Cloud Backup
- 🔒 Remote Device Management



Mobile Internet User Base

In million



Enterprise Business – Drives Sustainability



SEQRITE
Endpoint Security (EPS)



SEQRITE
Endpoint Security Cloud



SEQRITE
Unified Threat Management (UTM)



SEQRITE
Mobile Device Management (MDM)



SEQRITE
Endpoint Encryption Solutions



SEQRITE
Secure Web Gateway



Security Vulnerabilities



Insider Threats



Ransomware Attacks



Infected External Devices



Malicious Internet Traffic



Phishing Attacks



Data Breaches



Dos & DDos ATTACKS



ADVANCED PERSISTENT THREATS



MOBILE MALWARE & MALICIOUS
MOBILE APPS



PRO-ACTIVE SERVICES

- ▶ Technical Audit
- ▶ Security Management
- ▶ Compliance Audit
- ▶ Security Consulting
- ▶ Red Team Audit

ACTIVE SERVICES

- ▶ Real Time Monitoring
- ▶ Security Operations Centre (SOC) Operations

RE-ACTIVE SERVICES

- ▶ CERT as a Service
- ▶ Digital Forensics
- ▶ Incident Response

Improve
Market Share

Expand range of
Security Solutions

Strengthen
Sales Teams

Expand Channel
Partner network

Identify New SMB &
Enterprise
Opportunities

Safeguard digital assets
of Customers



Future opportunities



Turning Problems into Possibilities...

Quick Heal
Security Simplified

7 Million Ransomware
VS 5 Million Cryptojacking
Cryptojacking rises but Ransomware still #1
Threat for Consumers



SEQRITE

**Top 5 Industries
Targeted by Malware**



Cybersecurity Predictions - 2019

- Threats to become more **sophisticated** and equipped with advanced **AI-led capabilities**
- Increase in **web skimming attacks**
- Projected rise in **Ransomware** attacks targeting **critical infrastructure**
- An increase in targeted **IoT-based attacks**
- Increase in targeted **cybercrimes** during important public events
- **Cryptomining** and **cloud-based attacks** to rise
- **Mobile landscape** expected to become more threat-prone in 2019
- Rise in targeted attacks to exploit **supply chain vulnerabilities**
- Attacks on the **financial sector** to increase
- **Data protection** to become essential due to **data-centric attacks**


Future Opportunities

- **Government** working on strong **data protection regulations**
- **Enterprises** are increasingly adopting **IT security solutions** to combat advanced cyber-threats
- By 2022, **India's digital economy** is expected to grow to **USD 1 trillion**
- **Increase in Cyber Threats in 2018:**
 - Quick Heal detected **970+ million malware** targeting individual users
 - Seqrite blocked closed to **50 million cyber-threats** targeting **enterprise customers**
 - The year was headlined by **targeted cyber-attacks** and large scale **data breaches**
- **Increase in Mobile Transactions:** According to RBI data, **mobile wallet transactions** hit **16,108 crore** in **November 2018**
- Proliferation of **smart devices** will raise **cybersecurity risks**. By 2020, it is anticipated, **IoT** may comprise as many as **30 billion devices**
- By 2022, **6 billion people** will be **vulnerable** to **cyber-attacks**

Future Strategy



- Tailored products and service offerings for SMB and enterprise users
- Focus on manufacturing, BFSI, healthcare and hospitality industries
- Reach out to SMBs, identify new SMB opportunities, increase engagement with channel partners



- Special focus on Tier II and Tier III towns
- Increase penetration and adoption of security solutions by offering unique value propositions
- Enhance customer experience

- Ongoing efforts on new technologies such as IoT and home security automation
- 4 US patents to its credit; awaiting 3 patents in India
- Develop and promote software-as-a-service model

- Develop products for various platforms
- Monetize free solutions for mobile devices


- Focus on international expansion through consistent brand building and marketing effort
- Exploring opportunities in Africa, Middle East & South East Asia

Q3 & 9M FY19 Highlights




Q3 FY19 – Quarterly Consolidated Performance Highlights


Revenue (Rs. mln)




EBITDA (Rs. mln)




Margins (%)



PAT (Rs. mln)



Cash PAT* (Rs. mln)




* Cash PAT = PAT + Depreciation


As per Ind AS

9M FY19 – Annual Consolidated Performance Highlights


Revenue (Rs. mln)




EBITDA (Rs. mln)




Margins (%)



PAT (Rs. mln)



Cash PAT* (Rs. mln)




* Cash PAT = PAT + Depreciation


As per Ind AS

Segment Performance : Revenue Break-up

Retail (Rs. mln)




Enterprise & Govt. (Rs. mln)




Based on net revenues before adjusting for sales incentives

Segment Performance : Licenses Sold Analysis

Retail (in 000's)



Enterprise & Govt. (in 000's)



Q3 and 9M FY19 - Consolidated Profitability Statement

Particulars (Rs. mln)	Q3 FY19	Q3 FY18	YoY	9M FY19	9M FY18	YoY
Total Revenue	667.05	642.44	3.83%	2,289.25	1,996.23	14.68%
Direct Cost	34.32	35.45		111.16	104.44	
Gross Profit	632.73	606.99	4.24%	2,178.09	1,891.79	15.13%
Gross Margin	94.85%	94.48%	37 bps	95.14%	94.77%	38 bps
Operating Cost						
R&D Cost	131.83	133.63		413.67	412.29	
Sales and Marketing (S&M)	172.90	230.52		491.87	550.55	
General Administration (G&A)	120.92	128.16		379.75	380.00	
Total Expenditure	425.65	492.31	-13.54%	1,285.29	1,342.84	-4.29%
EBITDA	207.08	114.68	80.57%	892.80	548.95	62.64%
EBITDA Margin	31.04%	17.85%	1,319 bps	39.00%	27.50%	1,150 bps
Depreciation	59.79	68.20		179.17	200.02	
EBIT	147.29	46.48	216.89%	713.63	348.93	104.52%
EBIT Margin	22.08%	7.23%	1,485 bps	31.17%	17.48%	1,369 bps
Other Income	90.58	52.23		241.52	164.86	
PBT	237.87	98.71	140.98%	955.15	513.79	85.90%
Tax	79.25	32.18		314.38	175.52	
PAT	158.62	66.53	138.42%	640.77	338.27	89.43%
PAT Margin	23.78%	10.36%	1,342 bps	27.99%	16.95%	1,104 bps

NOTE: Certain figures have been re-grouped wherever necessary

Q3 and 9M FY19 - Consolidated Ratio Analysis

In %	Q3 FY19	Q3 FY18	9M FY19	9M FY18
Expenses				
Direct Cost / Revenue	5.15%	5.52%	4.86%	5.23%
R&D / Revenue	19.76%	20.80%	18.07%	20.65%
S&M / Revenue	25.92%	35.88%	21.49%	27.58%
G&A / Revenue	18.13%	19.95%	16.59%	19.04%
Total Cost / Revenue	63.81%	76.63%	56.14%	67.27%
Margin				
Gross Margin	94.85%	94.48%	95.14%	94.77%
EBIDTA	31.04%	17.85%	39.00%	27.50%
EBIT	22.08%	7.23%	31.17%	17.48%
PBT	35.66%	15.36%	41.72%	25.74%
PAT	23.78%	10.36%	27.99%	16.95%

NOTE: Certain figures have been re-grouped wherever necessary


Consolidated Balance Sheet

EQUITY AND LIABILITIES (Rs. mln)	31-Dec-18	31-Dec-17
Share Holder's Funds:		
Equity Share Capital	705.53	703.20
Reserves and Surplus	6,908.34	6,067.98
Total Shareholder Funds	7,613.87	6,771.18
Non-Current Liabilities		
Net employee defined benefit liabilities	19.20	25.42
Other Non Current Liabilities	19.53	0.00
Total Non-Current Liabilities	38.73	25.42
Current Liabilities:		
Trade and Other Payables	401.24	383.24
Other Financial Liabilities	16.53	9.83
Other Current Liabilities	103.96	96.03
Net employee defined benefit liabilities	16.47	13.69
Current Tax Liabilities (Net)	14.09	214.20
Total Current Liabilities	552.29	716.99
Total Equity & Liabilities	8,204.89	7,513.59

ASSETS (Rs mln)	31-Dec-18	31-Dec-17
Non-Current Assets:		
Property, plant and equipment	1,605.91	1,656.57
Capital work-in-progress	5.12	137.10
Intangible assets	88.58	43.57
Non-current financial assets		
Investments	301.53	66.66
Loan and Security Deposits	3.81	3.28
Bank Balances	4.09	3.49
Deferred tax assets (net)	77.51	65.24
Other non current assets	61.57	383.91
Total Non-Current Assets	2,148.12	2,359.82
Current assets:		
Inventories	58.59	55.10
Investment in Mutual Fund	3,275.42	2,807.69
Trade and other receivables	1,030.98	524.36
Bank Balances & Cash and Cash Equivalents	124.00	104.46
Investment in Fixed Deposit	1,413.36	1,514.17
Loans and Security Deposits	7.33	8.76
Interest accrued	61.82	50.53
Other Current assets	85.27	88.70
Total Current Assets	6,056.77	5,153.77
Total Assets	8,204.89	7,513.59

NOTE: Certain figures have been re-grouped wherever necessary

9M FY19 – Working Capital Analysis



Note:

- Net Working Capital Days for March 2018 = $[(\text{Net Working Capital} / \text{FY18 Sales}) * (365 \text{ days})]$
- Net Working Capital Days for September 2018 = $[(\text{Net Working Capital} / 6 \text{ Month Sales}) * (180 \text{ days})]$
- Net Working Capital Days for December 2018 = $[(\text{Net Working Capital} / 9 \text{ Month Sales}) * (270 \text{ days})]$

Q3 and 9M FY19 – Standalone Profitability Statement

Particulars (Rs. mln)	Q3 FY19	Q3 FY18	YoY	9M FY19	9M FY18	YoY
Total Revenue	659.05	635.88	3.64%	2,275.49	1,978.42	15.02%
Direct Cost	33.11	31.50		112.88	100.57	
Gross Profit	625.94	604.38	3.57%	2,162.61	1,877.85	15.16%
Gross Margin	94.98%	95.05%	-7 bps	95.04%	94.92%	12 bps
Operating Cost						
R&D Cost	131.83	133.63		413.67	412.29	
Sales and Marketing (S&M)	167.19	220.58		476.79	527.08	
General Administration (G&A)	117.47	118.99		367.19	362.28	
Total Expenditure	416.49	473.20		1,257.65	1,301.65	-3.38%
EBITDA	209.45	131.18	59.67%	904.96	576.20	57.06%
EBITDA Margin	31.78%	20.63%	1,115 bps	39.77%	29.12%	1,065 bps
Depreciation	59.74	67.94		179.00	199.67	
EBIT	149.71	63.24	136.73%	725.96	376.53	92.80%
EBIT Margin	22.72%	9.94%	1,277 bps	31.90%	19.03%	1,287 bps
Other Income	90.10	51.70		240.20	163.27	
PBT (Before Exceptional Items)	239.81	114.94	108.64%	966.16	539.80	78.98%
Exceptional Items	0.00	3.28		50.00	3.28	
PBT (After Exceptional Items)	239.81	111.66	114.77%	916.16	536.52	70.76%
Tax	78.88	31.99		313.78	174.98	
PAT	160.93	79.67	102.00%	602.38	361.54	66.62%
PAT Margin	24.42%	12.53%	1,189 bps	26.47%	18.27%	820 bps

NOTE: Certain figures have been re-grouped wherever necessary

Q3 and 9M FY19 – Standalone Ratio Analysis

In %	Q3 FY19	Q3 FY18	9M FY19	9M FY18
Expenses				
Direct Cost / Revenue	5.02%	4.95%	4.96%	5.08%
R&D / Revenue	20.00%	21.01%	18.18%	20.84%
S&M / Revenue	25.37%	34.69%	20.95%	26.64%
G&A / Revenue	17.82%	18.71%	16.14%	18.31%
Total Cost / Revenue	63.20%	74.42%	55.27%	65.79%
Margin				
Gross Margin	94.98%	95.05%	95.04%	94.92%
EBIDTA	31.78%	20.63%	39.77%	29.12%
EBIT	22.72%	9.95%	31.90%	19.03%
PBT (Before Exceptional Items)	36.39%	18.08%	42.46%	27.28%
PBT (After Exceptional Items)	36.39%	17.56%	40.26%	27.12%
PAT	24.42%	12.53%	26.47%	18.27%

NOTE: Certain figures have been re-grouped wherever necessary

Standalone Balance Sheet

EQUITY AND LIABILITIES (Rs. mln)	31-Dec-18	31-Dec-17
Share Holder's Funds:		
Equity Share Capital	705.53	703.20
Reserves and Surplus	6,999.98	6,266.82
Total Shareholder Funds	7,705.51	6,970.02
Non-Current Liabilities		
Net employee defined benefit liabilities	19.20	25.35
Other non current liabilities	19.53	0.00
Total Non-Current Liabilities	38.73	25.35
Current Liabilities:		
Trade and Other Payables	397.73	378.01
Other Financial Liabilities	27.87	12.58
Other Current Liabilities	100.57	94.26
Net employee defined benefit liabilities	16.47	13.69
Current Tax Liabilities (Net)	13.63	213.74
Total Current Liabilities	556.27	712.28
Total Equity & Liabilities	8300.51	7,707.65

ASSETS (Rs mln)	31-Dec-18	31-Dec-17
Non-Current Assets:		
Property, plant and equipment	1,605.54	1,655.50
Capital work-in-progress	5.12	137.10
Intangible assets	88.36	43.32
Non-current financial assets		
Investments	455.00	335.02
Loan and Security Deposits	3.81	3.18
Bank Balances	4.09	3.63
Deferred tax assets (net)	77.51	65.23
Non-current tax assets (net)	61.12	383.74
Total Non-Current Assets	2,300.55	2,626.72
Current assets:		
Inventories	45.93	47.85
Investment in Mutual Fund	3,275.42	2,807.69
Trade and other receivables	1,027.67	513.88
Bank Balances & Cash and Cash Equivalents	84.43	51.11
Investment in Fixed Deposit	1,413.36	1,514.17
Loans and Security Deposits	6.67	8.35
Interest accrued	61.82	50.53
Other Current assets	84.66	87.35
Total Current Assets	5,999.96	5,080.93
Total Assets	8,300.51	7,707.65


NOTE: Certain figures have been re-grouped wherever necessary

Q3 and 9M FY19 Consolidated Results – Return Ratio Analysis


Quick Heal
Security Simplified

SEORITE


Return on Capital Employed (%)



Return on Equity (%)



Shareholding Structure – December 2018



Historical Financial Performance



FY18 - Consolidated Profitability Statement

Particulars (Rs. mln)	FY18	FY17	Growth	YoY
Total Revenue	3,183.15	2,999.78	183.37	6.11%
Direct Cost	167.38	230.18	-62.80	-27.28%
Gross Profit	3,015.77	2,769.60	246.17	8.89%
Gross Margin	94.74%	92.33%		241 bps
Operating Cost				
R&D Cost	567.40	635.41	-68.02	-10.70%
Sales and Marketing (S&M)	735.69	728.52	7.17	0.98%
General Administration (G&A)	509.28	504.23	5.05	1.00%
Total Expenditure	1,812.36	1,868.16	-55.80	-2.99%
EBITDA	1,203.41	901.45	301.96	33.50%
EBITDA Margin	37.81%	30.05%		776 bps
Depreciation	269.27	309.45	-40.18	-12.98%
EBIT	934.14	591.99	342.15	57.80%
EBIT Margin	29.35%	19.73%		962 bps
Other Income				
– Others	234.06	284.49	-50.44	-17.73%
– Service Tax Credit	65.96	0.00	65.96	-
PBT (Before Exceptional Item)	1,234.16	876.49	357.67	40.81%
Exceptional Item	0.00	37.81	-37.81	-100.00%
PBT (After Exceptional Item)	1,234.16	838.68	395.49	47.16%
Tax	404.12	306.44	97.68	31.87%
PAT	830.05	532.24	297.81	55.96%
PAT Margin	26.08%	17.74%		834 bps


NOTE: Certain figures have been re-grouped wherever necessary

Consolidated Balance Sheet

EQUITY AND LIABILITIES (Rs. mln)	31-Mar-18	31-Mar-17	ASSETS (Rs. mln)	31-Mar-18	31-Mar-17
Share Holder's Funds:			Non-Current Assets:		
Equity Share Capital	703.88	701.02	Property, plant and equipment	1,611.97	1,782.23
Share application money pending allotment	0.00	0.06	Capital work-in-progress	138.72	135.89
Reserves and Surplus	6,534.79	5,915.53	Other Intangible assets	118.54	65.39
Total Shareholder Funds	7,238.67	6,616.61	Non-current financial assets		
Non-Current Liabilities			Investments	64.01	66.66
Net employee defined benefit liabilities	21.04	22.73	Loan and Security Deposits	3.28	4.50
Total Non-Current Liabilities	21.04	22.73	Bank Balances	2.92	1.83
Current Liabilities:			Deferred tax assets (net)	43.71	87.30
Trade and Other Payables	327.06	408.96	Non-current tax assets (net)	33.90	198.67
Other Financial Liabilities	11.99	13.16	Other non-current assets	0.14	46.12
Other Liabilities	132.60	136.25	Total Non-Current Assets	2,017.18	2,388.59
Net employee defined benefit liabilities	13.10	14.42	Current assets:		
Current Tax Liabilities (Net)	62.68	123.11	Inventories	56.24	79.40
Total Current Liabilities	547.43	695.90	Investment in Mutual Fund	3,000.78	1,750.82
Total Equity & Liabilities	7,807.14	7,335.24	Trade and other receivables	1,030.88	971.83
			Bank Balances & Cash and Cash Equivalents	122.14	195.04
			Investment in Fixed Deposit	1,507.24	1,898.66
			Loans and Security Deposits	8.72	6.21
			Interest accrued	39.00	8.73
			Other Current assets	24.96	35.96
			Total Current Assets	5,789.96	4,946.65
			Total Assets	7,807.14	7,335.24

NOTE: Certain figures have been re-grouped wherever necessary

Key Takeaways



Company :

Investor Relations Advisors :

Quick Heal

Security Simplified

CIN No: L72200MH1995PLC091408

Associate Company Secretary

Mr. Vinav Agarwal

cs@quickheal.co.in

+91-20-66813232

www.quickheal.co.in

Chief Financial Officer

Mr. Nitin Kulkarni

Nitin.Kulkarni@quickheal.co.in

+91-20-66813232

www.quickheal.co.in

SGA Strategic Growth Advisors

CIN - U74140MH2010PTC204285

Mr. Jigar Kavaiya / Mr. Rahul Agarwal

jigar.kavaiya@sgapl.net / rahul.agarwal@sgapl.net

+91 9920602034 / +91 9821438864

www.sgapl.net